{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T22:51:33Z","timestamp":1788994293313,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T00:00:00Z","timestamp":1588809600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T00:00:00Z","timestamp":1588809600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006606","name":"Natural Science Foundation of Tianjin City","doi-asserted-by":"publisher","award":["NO.15JCZDJC3500"],"award-info":[{"award-number":["NO.15JCZDJC3500"]}],"id":[{"id":"10.13039\/501100006606","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>While antifibrotic drugs significantly decrease lung function decline in idiopathic pulmonary fibrosis (IPF), there is still an unmet need to halt disease progression. Antioxidative therapy with N-acetylcysteine (NAC) is considered a potential additional therapy that can be combined with antifibrotics in some patients in clinical practice. However, data on the efficacy, tolerability, and safety of this combination are scarce. We performed a systematic review and meta-analysis to appraise the safety, tolerability, and efficacy of the combination compared to treatment with pirfenidone alone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically reviewed all the published studies with combined pirfenidone (PFD) and NAC (PFD\u2009+\u2009NAC) treatment in IPF patients. The primary outcomes referred to decline in pulmonary function tests (PFTs) and the rates of IPF patients with side effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the meta-analysis, 6 studies with 319 total IPF patients were included. The PFD\u2009+\u2009NAC group was comparable to the PFD alone group in terms of the predicted forced vital capacity (FVC%) and predicted diffusion capacity for carbon monoxide (DLco%) from treatment start to week 24. Side effects and treatment discontinuation rates were also comparable in both groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This systematic review and meta-analysis suggests that combination with NAC does not alter the efficacy, safety, or tolerability of PFD in comparison to PFD alone in IPF patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12890-020-1121-2","type":"journal-article","created":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T07:03:17Z","timestamp":1588834997000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Efficacy, safety, and tolerability of combined pirfenidone and N-acetylcysteine therapy: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"20","author":[{"given":"Hanyu","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawei","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bonella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kreuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ute","family":"Oltmanns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuren","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouchun","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luqing","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,7]]},"reference":[{"issue":"2","key":"1121_CR1","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1164\/rccm.201506-1063ST","volume":"192","author":"G Raghu","year":"2015","unstructured":"Raghu G, Rochwerg B, Zhang Y, Garcia CAC, Azuma A, Behr J, Brozek JL, Collard HR, Cunningham W, Homma S, et al. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis: an update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 2015;192(2):e3\u2013e19.","journal-title":"Am J Respir Crit Care Med"},{"issue":"120","key":"1121_CR2","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1183\/09059180.00001111","volume":"20","author":"CJ Schaefer","year":"2011","unstructured":"Schaefer CJ, Ruhrmund DW, Pan L, Seiwert SD, Kossen K. Antifibrotic activities of pirfenidone in animal models. Eur Respir Rev. 2011;20(120):85\u201397.","journal-title":"Eur Respir Rev"},{"key":"1121_CR3","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","volume":"377","author":"PW Noble","year":"2011","unstructured":"Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE, Lancaster L, Sahn SA, Szwarcberg J, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet (London, England). 2011;377:1760\u20139.","journal-title":"Lancet (London, England)"},{"key":"1121_CR4","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","volume":"370","author":"TE King","year":"2014","unstructured":"King TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2083\u201392.","journal-title":"N Engl J Med"},{"issue":"1","key":"1121_CR5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S2213-2600(16)30326-5","volume":"5","author":"SD Nathan","year":"2017","unstructured":"Nathan SD, Albera C, Bradford WZ, Costabel U, Glaspole I, Glassberg MK, Kardatzke DR, Daigl M, Kirchgaessler KU, Lancaster LH, et al. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. Lancet Respir Med. 2017;5(1):33\u201341.","journal-title":"Lancet Respir Med"},{"issue":"3","key":"1121_CR6","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.resinv.2015.11.004","volume":"54","author":"Y Muramatsu","year":"2016","unstructured":"Muramatsu Y, Sugino K, Ishida F, Tatebe J, Morita T, Homma S. Effect of inhaled N-acetylcysteine monotherapy on lung function and redox balance in idiopathic pulmonary fibrosis. Respir Investig. 2016;54(3):170\u20138.","journal-title":"Respir Investig"},{"issue":"22","key":"1121_CR7","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1401739","volume":"370","author":"FJ Martinez","year":"2014","unstructured":"Martinez FJ, de Andrade JA, Anstrom KJ, King TE, Raghu G. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2093\u2013101.","journal-title":"N Engl J Med"},{"key":"1121_CR8","unstructured":"Bonella F, Wessendorf T, Costabel U. Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis. Eur Respir J. 2013;42:P3808."},{"key":"1121_CR9","doi-asserted-by":"crossref","unstructured":"Jo HE, Glaspole I, Grainge C, Goh N, Hopkins PM, Moodley Y, Reynolds PN, Chapman S, Walters EH, Zappala C, et al. Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry. Eur Respir J. 2017;49(2):1601592.","DOI":"10.1183\/13993003.01592-2016"},{"key":"1121_CR10","doi-asserted-by":"crossref","unstructured":"Kreuter M, Swigris J, Pittrow D, Geier S, Klotsche J, Prasse A, Wirtz H, Koschel D, Andreas S, Claussen M, et al. Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry. Respir Res. 2017;18(1):139.","DOI":"10.1186\/s12931-017-0621-y"},{"issue":"6","key":"1121_CR11","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S2213-2600(16)30044-3","volume":"4","author":"J Behr","year":"2016","unstructured":"Behr J, Bendstrup E, Crestani B, G\u00fcnther A, Olschewski H, Sk\u00f6ld CM, Wells A, Wuyts W, Koschel D, Kreuter M, et al. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med. 2016;4(6):445\u201353.","journal-title":"Lancet Respir Med"},{"key":"1121_CR12","volume-title":"Effect of pirfenidone combined with acetylcysteine on idiopathic pulmonary fibrosis [M]: Hebei Medical University","author":"L Ma","year":"2018","unstructured":"Ma L. Effect of pirfenidone combined with acetylcysteine on idiopathic pulmonary fibrosis [M]: Hebei Medical University; 2018. [In Chinese]."},{"key":"1121_CR13","unstructured":"Mao ZX. Clinical observation of pirfenidone combined with acetylcysteine in the treatment of idiopathic pulmonary interstitial fibrosis Drugs & Clinic. 2018;8(33). [In Chinese]."},{"key":"1121_CR14","doi-asserted-by":"crossref","unstructured":"Sakamoto S, Muramatsu Y, Satoh K, Ishida F, Kikuchi N, Sano G, Sugino K, Isobe K, Takai Y, Homma S. Effectiveness of combined therapy with pirfenidone and inhaled N-acetylcysteine for advanced idiopathic pulmonary fibrosis: a case-control study. Respirology (Carlton, Vic). 2015;20(3):445\u201352.","DOI":"10.1111\/resp.12477"},{"issue":"6","key":"1121_CR15","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","volume":"183","author":"G Raghu","year":"2011","unstructured":"Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, et al. An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788\u2013824.","journal-title":"Am J Respir Crit Care Med"},{"key":"1121_CR16","doi-asserted-by":"crossref","unstructured":"Huang H, Dai HP, Kang J, Chen BY, Sun TY, Xu ZJ. Double-Blind Randomized Trial of Pirfenidone in Chinese Idiopathic Pulmonary Fibrosis Patients. Medicine (Baltimore). 2015;94(42):e1600.","DOI":"10.1097\/MD.0000000000001600"},{"issue":"3","key":"1121_CR17","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.resinv.2015.10.001","volume":"54","author":"R Okuda","year":"2016","unstructured":"Okuda R, Matsushima H, Oba T, Kawabe R, Matsubayashi M, Amano M, Nishizawa T, Honda K. Efficacy and safety of inhaled N-acetylcysteine in idiopathic pulmonary fibrosis: a prospective, single-arm study. Respir Investig. 2016;54(3):156\u201361.","journal-title":"Respir Investig"},{"issue":"9","key":"1121_CR18","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603\u20135.","journal-title":"Eur J Epidemiol"},{"key":"1121_CR19","first-page":"126","volume-title":"Review: Cochrane handbook for systematic reviews for interventions, version 5.1.0, published 3\/2011","author":"JJ Shuster","year":"2011","unstructured":"Shuster JJ: Review: Cochrane handbook for systematic reviews for interventions, version 5.1.0, published 3\/2011. Julian P.T. Higgins and Sally Green, Editors. 2011, 2(2):126\u2013130."},{"issue":"3","key":"1121_CR20","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1159\/000363064","volume":"88","author":"U Oltmanns","year":"2014","unstructured":"Oltmanns U, Kahn N, Palmowski K, Trager A, Wenz H, Heussel CP, Schnabel PA, Puderbach M, Wiebel M, Ehlers-Tenenbaum S, et al. Pirfenidone in idiopathic pulmonary fibrosis: real-life experience from a German tertiary referral center for interstitial lung diseases. Respiration. 2014;88(3):199\u2013207.","journal-title":"Respiration"},{"key":"1121_CR21","doi-asserted-by":"crossref","unstructured":"Homma S, Kondoh Y, Kato M, Hoshino T, Mukae H, Bando M, Suda T, Kido T, Tanino Y, Kishaba T, et al. Efficacy of combined therapy with pirfenidone and inhaled N-acetylcysteine for idiopathic pulmonary fibrosis: a randomized controlled phase 3 trial. Eur Respir J. 2018;52:PA4795.","DOI":"10.1183\/13993003.congress-2018.PA4795"},{"issue":"1","key":"1121_CR22","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12931-019-1020-3","volume":"20","author":"M Kreuter","year":"2019","unstructured":"Kreuter M, Swigris J, Pittrow D, Geier S, Klotsche J, Prasse A, Wirtz H, Koschel D, Andreas S, Claussen M, et al. The clinical course of idiopathic pulmonary fibrosis and its association to quality of life over time: longitudinal data from the INSIGHTS-IPF registry. Respir Res. 2019;20(1):59.","journal-title":"Respir Res"},{"key":"1121_CR23","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s12916-015-0478-1","volume":"13","author":"C Vancheri","year":"2015","unstructured":"Vancheri C. Idiopathic pulmonary fibrosis and cancer: do they really look similar? BMC Med. 2015;13:220.","journal-title":"BMC Med"},{"issue":"21","key":"1121_CR24","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1056\/NEJMoa042976","volume":"353","author":"M Demedts","year":"2005","unstructured":"Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, MacNee W, Thomeer M, Wallaert B, Laurent F, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2005;353(21):2229\u201342.","journal-title":"N Engl J Med"},{"issue":"21","key":"1121_CR25","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1056\/NEJMoa1113354","volume":"366","author":"G Raghu","year":"2012","unstructured":"Raghu G, Anstrom KJ, King TE, Lasky JA, Martinez FJ. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012;366(21):1968\u201377.","journal-title":"N Engl J Med"},{"issue":"12","key":"1121_CR26","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1164\/rccm.201505-1010OC","volume":"192","author":"JM Oldham","year":"2015","unstructured":"Oldham JM, Ma SF, Martinez FJ, Anstrom KJ, Raghu G, Schwartz DA, Valenzi E, Witt L, Lee C, Vij R, et al. TOLLIP, MUC5B, and the response to N-Acetylcysteine among individuals with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2015;192(12):1475\u201382.","journal-title":"Am J Respir Crit Care Med"},{"key":"1121_CR27","doi-asserted-by":"crossref","unstructured":"Cottin V, Koschel D, Gunther A, Albera C, Azuma A, Skold CM, Tomassetti S, Hormel P, Stauffer JL, Strombom I, et al. Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study. ERJ open research. 2018;4(4):00084\u20132018.","DOI":"10.1183\/23120541.00084-2018"},{"key":"1121_CR28","doi-asserted-by":"publisher","first-page":"17074","DOI":"10.1038\/nrdp.2017.74","volume":"3","author":"FJ Martinez","year":"2017","unstructured":"Martinez FJ, Collard HR, Pardo A, Raghu G, Richeldi L, Selman M, Swigris JJ, Taniguchi H, Wells AU. Idiopathic pulmonary fibrosis. Nat Rev Dis Primers. 2017;3:17074.","journal-title":"Nat Rev Dis Primers"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-020-1121-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-020-1121-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-020-1121-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T19:21:27Z","timestamp":1620328887000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-020-1121-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,7]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1121"],"URL":"https:\/\/doi.org\/10.1186\/s12890-020-1121-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.18027\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.18027\/v2","asserted-by":"object"}]},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,7]]},"assertion":[{"value":"26 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"128"}}